Impacts
- 1 results
Search results
-
EU approval of epcoritamab for treatment of relapsed/refractory lymphoma
Linton, K. (Participant)
Impact: Policy
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
Kim M. Linton*, Umberto Vitolo, Wojciech Jurczak, Pieternella J. Lugtenburg, Emmanuel Gyan, Anna Sureda, Jacob Haaber Christensen, Brian Hess, Hervé Tilly, Raul Cordoba, David John Lewis, Craig Okada, Martin Hutchings, Michael Roost Clausen, Juan Manuel Sancho, Tara Cochrane, Sirpa Leppä, Martine E.D. Chamuleau, Diana Gernhardt, Işıl Altıntaş
*Corresponding author for this work
- Candiolo Cancer Institute IRCCS
- Maria Sklodowska-Curie National Research Institute of Oncology
- Erasmus MC
- CHU Tours
- Universitat de Barcelona
- Odense University Hospital
- The University of South Carolina
- UMR CNRS 6634-Université de Rouen
- Health Research Institute-Fundación Jiménez Díaz University Hospital
- Oregon Health and Science University
- University of Copenhagen
- Vejle Hospital
- Hospital Germans Trias i Pujol
- Gold Coast University Hospital
- University of Helsinki
- VU University Medical Center
- Genmab
- Genmab B.V., Netherlands
- AbbVie Inc
- Genmab A/S
- Université de Paris
- University of Nebraska Medical Center
Research output: Contribution to journal › Article › peer-review